Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

Findings are Consistent with China Phase 3 Trials Results, and Support China NDA Submission
SAN FRANCISCO, March 30, 2017 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from two Phase 2 studies in China of roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD) were published in the journal Nephrology Dialysis Transplantation. In these studies, in dialysis-dependent, and in non-dialysis-dependent CKD patients, roxadustat corrected and maintained hemoglobin levels regardless of the patients’ baseline iron repletion status, and levels of C-reactive protein (CRP), a marker of infl…

Source: Original Article